Hartman Institute for Therapeutic Organ Regeneration

Design and Synthesis of 3,5-Disubstituted 1,2,4-Oxadiazole Containing Retinoids from a Retinoic Acid Receptor Agonist.

TitleDesign and Synthesis of 3,5-Disubstituted 1,2,4-Oxadiazole Containing Retinoids from a Retinoic Acid Receptor Agonist.
Publication TypeJournal Article
Year of Publication2011
AuthorsDas BC, Tang X-Y, Sanyal S, Mohapatra S, Rogler P, Nayak S, Evans T
JournalTetrahedron Lett
Volume52
Issue19
Pagination2433-2435
Date Published2011 May 11
ISSN0040-4039
Abstract

<p>We previously synthesized novel retinoid libraries, and after screening for bioactivity found one compound BT10 that functions as a specific agonist for retinoic acid receptors. This lead compound was further derivatized using SAR and LRD to obtain 3,5-disubstituted-1,2,4-oxadiazole-containing retinoids. The new oxadiazole (amide bioisosters)-containing retinoids (compounds 1, 2, 3, 4, 5, and 6) were synthesized in 42-65% yield by reacting with (E)-4-((3-ethyl,2-4,4,4-trimethylcyclohex-2-enylidene)methyl)benzoic acid and phenyl substituted amidoxime in DMF using CDI as the coupling reagent. The biological activities of the synthesized compounds are currently being evaluated.</p>

DOI10.1016/j.tetlet.2011.03.011
Alternate JournalTetrahedron Lett
PubMed ID21765558
PubMed Central IDPMC3135900
Grant ListR37 HL056182 / HL / NHLBI NIH HHS / United States
R37 HL056182-15 / HL / NHLBI NIH HHS / United States

Weill Cornell Medicine
Hartman Institute for Therapeutic Organ Regeneration
1300 York Ave, Box 136 New York, NY 10065